The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer
The improvement in treatment strategies and outcomes in small cell lung cancer (SCLC) has lagged behind other cancers. The addition of immune checkpoint inhibitors (ICIs), durvalumab and atezolizumab, to the platinum-based chemotherapy in frontline setting has improved the survival in extensive stag...
Main Authors: | Saurav Verma, Sympascho Young, Alexander V. Louie, David Palma, Daniel Breadner |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-08-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359231192399 |
Similar Items
-
Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
by: Huanhuan Li, et al.
Published: (2023-08-01) -
Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
by: Zhaoliang Xie, et al.
Published: (2023-06-01) -
Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex
by: Vikram Jairam, MD, et al.
Published: (2024-04-01) -
Feasibility and long-term outcomes of post-chemotherapy-based consolidation radiotherapy in extensive stage small-cell lung cancer
by: Chen Jie, et al.
Published: (2023-09-01) -
‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review
by: Saurav Verma, et al.
Published: (2023-04-01)